Abstract
To highlight the societal burden of HBV infection in South Korea, we estimated the annual societal costs of HBV-related diseases for the year 2005. For the economic costs of HBV-infection-related diseases estimate, baseline data was collected from the Health Insurance Review and Assessment Service (HIRA) database. To complement data from the HIRA database, hospital charts from sample hospitals was reviewed and patient surveys were conducted. In 2005, the societal cost of HBV infection was 1.937 trillion KRW, including 474,642 million KRW of direct costs and 1.463 trillion KRW of indirect costs. The cost breakdown by disease was CHB at 465,167 million KRW, cirrhosis at 533,449 million KRW, hepatocellular carcinoma at 863,940 million KRW, and liver transplantation at 74,635 million KRW. The estimated amount is equivalent to 0.24% of the 2005 Korean GDP. This analysis emphasizes how important the prevention and treatment of these diseases are from the perspectives of the Korean society.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kane M. Global status of hepatitis B immunization. Lancet. 1996;348(9029):696.
Song BC, Kim SH, Kim H, et al. Prevalence of naturally occurring surface antigen variants of hepatitis B virus in Korean patients infected chronically. J Med Virol. 2005;76:194–202.
Lee DH, Kim JH, Nam JJ, Kim HR, Shin HR. Epidemiological findings of hepatitis B infection based on 1998 National Health and Nutrition Survey in Korea. J Korean Med Sci. 2002;17:457–462.
Yang BM, Paik SW, Hahn OS, Yi DH, Choi MS, Payne S. Economic evaluation of the societal costs of hepatitis B in South Korea. J Gastroenterol Hepatol. 2001;16(3):301–308.
National Statistical Office. 2005 cause of death statistics. Seoul: National Statistical Office; 2007.
Korean Network For Organ Sharing (KONOS): Annual report. Seoul; 2006.
Korea Institute of Health and Social Affairs: The Third Korea National Health and Nutrition Examination Survey, 2005-Health Service Utilization. Seoul: Ministry of Health and Welfare, Korea Institute of Health and Social Affairs; 2006.
Lee TA, Veenstra DL, Iloeje UH, Sullivan SD. Cost of chronic hepatitis B infection in the United States. J Clin Gastroenterol. 2004;38(10 Suppl):S144–S147.
Hsieh CR, Kuo CW. Cost of chronic hepatitis B virus infection in Taiwan. J Clin Gastroenterol. 2004;38(10 Suppl):S148–S152.
Li SC, Ong SC, Lim SG, et al. A cost comparison of management of chronic hepatitis B and its associated complications in Hong Kong and Singapore. J Clin Gastroenterol. 2004;38(10 Suppl):S136–S143.
Zhiqiang G, Zhaohui D, Qinhuan W, et al. Cost of chronic hepatitis B infection in China. J Clin Gastroenterol. 2004;38(10 Suppl):S175–S178.
Yang BM, Kim CH, Kim JY. Cost of chronic hepatitis B infection in South Korea. J Clin Gastroenterol. 2004;38(10 Suppl):S153–S157.
Acknowledgments
This study was supported in part by a research grant from the Novartis Pharmaceuticals Corporation.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yang, BM., Kim, D.J., Byun, K.S. et al. The Societal Burden of HBV-Related Disease: South Korea. Dig Dis Sci 55, 784–793 (2010). https://doi.org/10.1007/s10620-009-0786-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-009-0786-4